The patent is for the process of manufacturing antigen-specific T-reg cells, one of several modalities of engineered Treg cells PolTREG is working on.
Antigen specific Treg cells have been “trained” to recognize a patient’s biomarkers for a disease – for instance type 1 diabetes – and the expectation is this will make them more targeted as they go about their task of regulating the immune system.
PolTREG’s programme with polyclonal cells is the most advanced, but we are also developing all types of engineered Treg cells, including TCR-Tregs and CAR-Tregs.
In September, we announced the launch of a study with CAR-Treg cells in a humanized mouse model of neuroinflammatory disease. We expect the data from this study by March 30, 2025, and will then think about the pathway to clinical evaluation.
